[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Pepeu et al., 2004 - Google Patents

Acetylcholine: I Muscarinic receptors

Pepeu et al., 2004

Document ID
14099885037494496884
Author
Pepeu G
Giovannini M
et al.
Publication year
Publication venue
From messengers to molecules: memories are made of these

External Links

Continue reading at scholar.google.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids

Similar Documents

Publication Publication Date Title
Albuquerque et al. Mammalian nicotinic acetylcholine receptors: from structure to function
Tzavara et al. M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related central nervous system pathologies
Leonard et al. Nicotinic receptor function in schizophrenia
Das et al. Hedgehog agonist therapy corrects structural and cognitive deficits in a Down syndrome mouse model
Quik et al. Role of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders
Gupta et al. Novel targets explored in the treatment of alcohol withdrawal syndrome
Porter-Stransky et al. Noradrenergic transmission at alpha1-adrenergic receptors in the ventral periaqueductal gray modulates arousal
Yamada et al. Novel insights into M5 muscarinic acetylcholine receptor function by the use of gene targeting technology
Ochoa et al. Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking
Radek et al. Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists
Mossa et al. Developmental impaired Akt signaling in the Shank1 and Shank3 double knock-out mice
Zhou et al. Neuregulin 3 signaling mediates nicotine-dependent synaptic plasticity in the orbitofrontal cortex and cognition
Rao et al. Reduced ocular dominance plasticity and long‐term potentiation in the developing visual cortex of protein kinase A RIIα mutant mice
Li et al. GABAB receptors and drug addiction: Psychostimulants and other drugs of abuse
Abarkan et al. The glutamate receptor GluK2 contributes to the regulation of glucose homeostasis and its deterioration during aging
Wu et al. Transgenic mice over-expressing GABABR1a receptors acquire an atypical absence epilepsy-like phenotype
Pepeu et al. Acetylcholine: I Muscarinic receptors
Zhang et al. Temporal effect of manipulating NeuroD1 expression with the synthetic small molecule KHS101 on morphine contextual memory
Kumar et al. Altering opioid neuromodulation in the songbird basal ganglia modulates vocalizations
Digala et al. Acetylcholine
Latif‐Hernandez et al. A TrkB and TrkC partial agonist restores deficits in synaptic function and promotes activity‐dependent synaptic and microglial transcriptomic changes in a late‐stage Alzheimer's mouse model
US20070197583A1 (en) Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction
Marks et al. Presynaptic nicotinic acetylcholine receptors: subtypes and functions
Scott Serotonin 1B Receptor Modulation of cocaine Abuse-Like Behavior in Female Rats Before and After Abstinence from Self-Administration
Brown Nicotinic mechanisms mediating prepulse inhibition of the acoustic startle response (Spine title: Nicotinic mechanisms mediating PPI of the startle response)